Female urogenital chlamydia: Epidemiology, chlamydia on pregnancy, current diagnosis, and treatment. (March 2022)

• Record Type: Journal Article
• Authors: Tjahyadi, Dian; Ropii, Bejo; Tjandraprawira, Kevin Dominique; Parwati, Ida; Djuwantono, Tono; Permadi, Wiryawan; Li, Tinchiu
• Is Part Of: Annals of medicine and surgery. Volume 75(2022)
• Publication Date: 2022-03
• Subjects: Urogenital chlamydia -- Chlamydia trachomatis; Surgery -- Periodicals; Medicine -- Periodicals; General Surgery -- Periodicals; Education, Medical -- Periodicals; Periodicals; 617
• DOI: 10.1016/j.amsu.2022.103448
• Languages: English
• ISSNs: 2049-0801

Abstract

Abstract: Female urogenital chlamydia is a disease caused by Chlamydia trachomatis infection in the female urogenital tract. It is a common bacterial sexually transmitted disease. The bacteria is transmitted through sexual contact with an infected partner or from mother to newborn during vaginal delivery. The prevalence varies among studies and the number is possibly higher due to the lack of massive screening. Many patients were asymptomatic and still be able to transmit the disease. The undiagnosed and untreated disease could cause pelvic inflammatory disease, which leads to infertility, ectopic pregnancy, and chronic pelvic pain. The prevalence among pregnant women is similar to non-pregnant women, therefore chlamydia screening in pregnant women is highly recommended. The nucleic acid amplification test is the most reliable method for the diagnosis due to high sensitivity. The current treatment is given by prescribing antibiotics. Highlights: Female urogenital chlamydia is caused by Chlamydia trachomatis . Urogenital chlamydia affects young and sexually active women. Female urogenital chlamydia is diagnosed through indirect methods (serology-based tests) and direct methods (culture). Treatment of chlamydia consists of antibiotics with doxycycline being the first-line choice.